AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25392649 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaporization of ovarian endometriomas using plasma energy
Number of subjects: 22
Study 25392936 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperfiltering adolescents with T1D (GFR ≥ 135 ml/min/1.73 m²)
Number of subjects: 142
Study 25392936 — intervention group
Group type: EXPERIMENTAL
Intervention: Normofiltering adolescents with T1D (GFR < 135 ml/min/1.73 m²)
Number of subjects: 142
Study 25392936 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (HC)
Number of subjects: 142
Study 25393047 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port sleeve gastrectomy (SPSG)
Number of subjects: 16
Study 25393157 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure-related complications during islet transplantation
Number of subjects: 26
Study 25393297 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Onset (EO) MDD (18-29 years old)
Number of subjects: 61
Study 25393297 — intervention group
Group type: EXPERIMENTAL
Intervention: Later Onset (LO) MDD (30-45 years old)
Number of subjects: 61
Study 25393297 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls (HCs)
Number of subjects: 61
Study 25393520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent therapy (n = 118)
Number of subjects: 217
Study 25393520 — intervention group
Group type: COMPARATOR
Intervention: Daily therapy (n = 99)
Number of subjects: 217
Study 25393536 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g/d omega-3 acid ethyl esters (P-OM3) for 8 weeks
Number of subjects: 15
Study 25393601 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and care strategy
Number of subjects: 1745
Study 25393601 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1745
Study 25393640 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (0.6 mg/d for 2 weeks, followed by 1.2 mg/d) in addition to metformin (1500 mg/d)
Number of subjects: 20
Study 25393648 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat 400 mg orally once daily for 14 days
Number of subjects: 20
Study 25393648 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat
Number of subjects: 20
Study 25394029 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC) plus 2 nucleoside reverse-transcriptase inhibitors (NRTIs)
Number of subjects: 87
Study 25394029 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (MVC) plus 2 NRTIs
Number of subjects: 87
Study 25394040 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC 100 mg
Number of subjects: 30
Study 25394040 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC 200 mg
Number of subjects: 30
Study 25394040 — intervention group
Group type: COMPARATOR
Intervention: EFV
Number of subjects: 30
Study 25394040 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC
Number of subjects: 30
Study 25394040 — intervention group
Group type: COMPARATOR
Intervention: MVC
Number of subjects: 30
Study 25394054 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV-based HAART
Number of subjects: 357
Study 25394054 — intervention group
Group type: COMPARATOR
Intervention: LPV/r-based HAART
Number of subjects: 357
Study 25394093 — intervention group
Group type: EXPERIMENTAL
Intervention: LPV/r monotherapy OD (LPVrMOD)
Number of subjects: 9
Study 25394116 — intervention group
Group type: EXPERIMENTAL
Intervention: ART with TB co-infection
Number of subjects: 812
Study 25394116 — intervention group
Group type: EXPERIMENTAL
Intervention: ART without TB co-infection
Number of subjects: 812
Study 25394116 — intervention group
Group type: COMPARATOR
Intervention: Retention in care (both groups)
Number of subjects: 812
Study 25394116 — intervention group
Group type: COMPARATOR
Intervention: Mortality (both groups)
Number of subjects: 812
Study 25394116 — intervention group
Group type: COMPARATOR
Intervention: CD4 cell count increase during treatment
Number of subjects: 812
Study 25394136 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoglobulin at birth and complete vaccine schedule during the first six months of life
Number of subjects: 35
Study 25394136 — intervention group
Group type: COMPARATOR
Intervention: Immunoglobulin and complete vaccine schedule
Number of subjects: 35
Study 25394136 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine or tenofovir/emtricitabine during pregnancy
Number of subjects: 35
Study 25394136 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine during the last trimester
Number of subjects: 35
Study 25394537 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin for at least 6 months
Number of subjects: 15
Study 25395187 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 329
Study 25395260 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplantation from HBsAg(+) donors without HBV prophylaxis (n=20)
Number of subjects: 129
Study 25395260 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplantation from HBsAg(+) donors with lamivudine alone
Number of subjects: 129
Study 25395260 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplantation from HBsAg(+) donors with lamivudine in combination with HBV immunoglobulin
Number of subjects: 129
Study 25395260 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney transplantation from HBsAg(+) donors
Number of subjects: 129
Study 25395260 — intervention group
Group type: COMPARATOR
Intervention: Kidney transplantation from HBsAg(-) donors
Number of subjects: 129
Study 25395425 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibritumomab tiuxetan consolidation after 3 cycles of CHOP plus IFRT
Number of subjects: 46
Study 25395425 — intervention group
Group type: COMPARATOR
Intervention: CHOP chemotherapy plus IFRT
Number of subjects: 46
Study 25395425 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 46
Study 25395429 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinaciclib at 30 mg/m²
Number of subjects: 27
Study 25395429 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinaciclib at 40 mg/m²
Number of subjects: 27
Study 25395429 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinaciclib at 50 mg/m²
Number of subjects: 27
Study 25395429 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinaciclib (overall)
Number of subjects: 27
Study 25396060 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (25(OH)D levels <20 ng/mL)
Number of subjects: 201
Study 25396060 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency
Number of subjects: 201
Study 25396065 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab (SRI responders, n=761)
Number of subjects: 1684
Study 25396067 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 201
Study 25396067 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 201
Study 25397516 — intervention group
Group type: EXPERIMENTAL
Intervention: DRV/COBI 800/150 mg qd plus two fully active N[t]RTIs
Number of subjects: 295
Study 25397527 — intervention group
Group type: EXPERIMENTAL
Intervention: etravirine (ETR) 200 mg bid with an optimised background regimen (BR) excluding DRV/r or NRTIs only
Number of subjects: 211
Study 25398082 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of unlicensed healthcare providers in zinc treatment and diarrhoea management
Number of subjects: 2
Study 25398099 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring for delirium in clinical routine
Number of subjects: 868
Study 25398099 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a validated delirium score
Number of subjects: 868
Study 25398099 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual practice of delirium monitoring
Number of subjects: 868
Study 25398099 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation levels
Number of subjects: 868
Study 25398099 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain assessment tools implementation
Number of subjects: 868
Study 25398099 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain in patients
Number of subjects: 868
Study 25398578 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization in cognitive and behavioral units
Number of subjects: 0
Study 25398578 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments at months 3, 6, and 12
Number of subjects: 0
Study 25398578 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up for 12 months post-hospitalization
Number of subjects: 0
Study 25398578 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of rehospitalization for behavioral disorders
Number of subjects: 0
Study 25398652 — intervention group
Group type: EXPERIMENTAL
Intervention: 2013 state health department survey
Number of subjects: 0
Study 25398652 — intervention group
Group type: EXPERIMENTAL
Intervention: Top ways to encourage EBDM use
Number of subjects: 0
Study 25398652 — intervention group
Group type: EXPERIMENTAL
Intervention: Most important items for applying EBDM
Number of subjects: 0
Study 25398832 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine, bortezomib and dexamethasone
Number of subjects: 0
Study 25399249 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy with adaptive difficulty levels
Number of subjects: 6
Study 25399542 — intervention group
Group type: EXPERIMENTAL
Intervention: Large serrated polyps (≥10 mm in diameter)
Number of subjects: 12955
Study 25399542 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced adenomas
Number of subjects: 12955
Study 25399542 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-advanced adenomas
Number of subjects: 12955
Study 25399542 — intervention group
Group type: EXPERIMENTAL
Intervention: Large serrated polyps
Number of subjects: 12955
Study 25399542 — intervention group
Group type: EXPERIMENTAL
Intervention: Large serrated polyps left in situ
Number of subjects: 12955
Study 25399779 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (administered immediately after anaesthesia induction)
Number of subjects: 1095
Study 25399779 — intervention group
Group type: COMPARATOR
Intervention: Levosimendan (administered later after postoperative ICU admission)
Number of subjects: 1095
Study 25400468 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant continuous infusion of 5-fluorouracil for five weeks and concomitant radiotherapy followed by laparoscopic mesorectal excision.
Number of subjects: 176
Study 25400468 — intervention group
Group type: EXPERIMENTAL
Intervention: Withholding adjuvant chemotherapy after complete response following standard neoadjuvant chemoradiotherapy and laparoscopic mesorectal excision.
Number of subjects: 176
Study 25400592 — intervention group
Group type: EXPERIMENTAL
Intervention: High aerobic intensity training (HIT)
Number of subjects: 53
Study 25400592 — intervention group
Group type: COMPARATOR
Intervention: No training
Number of subjects: 53
Study 25401382 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab for remission induction
Number of subjects: 0
Study 25401382 — intervention group
Group type: COMPARATOR
Intervention: Rituximab for remission maintenance
Number of subjects: 0
Study 25401382 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance therapy
Number of subjects: 0
Study 25401382 — intervention group
Group type: COMPARATOR
Intervention: Standard therapies
Number of subjects: 0
Study 25401784 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate
Number of subjects: 286
Study 25402214 — intervention group
Group type: EXPERIMENTAL
Intervention: STEMO (specialized ambulance)
Number of subjects: 6182
Study 25402214 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 6182
Study 25402214 — intervention group
Group type: EXPERIMENTAL
Intervention: Golden hour thrombolysis
Number of subjects: 6182
Study 25402221 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox 30 mg/kg/d
Number of subjects: 16
Study 25402488 — intervention group
Group type: EXPERIMENTAL
Intervention: (131)I-CLR1404, 370 MBq single injection
Number of subjects: 8
Study 25402488 — intervention group
Group type: EXPERIMENTAL
Intervention: (131)I-CLR1404, 740 MBq predicted administration
Number of subjects: 8
Study 25403092 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI) with pre-dilation (BAV)
Number of subjects: 0
Study 25403092 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter aortic valve implantation (TAVI) without pre-dilation (BAV)
Number of subjects: 0
Study 25403209 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 μg/kg per day of recombinant human IL-15 (rhIL-15) for 12 consecutive days
Number of subjects: 0
Study 25403209 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg per day of recombinant human IL-15 (rhIL-15) for 12 consecutive days
Number of subjects: 0
Study 25403209 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 μg/kg per day of recombinant human IL-15 (rhIL-15) for 12 consecutive days
Number of subjects: 0
Study 25403209 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human IL-15 (rhIL-15) administration
Number of subjects: 0
Study 25403217 — intervention group
Group type: EXPERIMENTAL
Intervention: Atu027 (10 escalating doses, 0.336 mg/kg, intravenous infusions twice per week during a 28-day cycle)
Number of subjects: 34
Study 25403550 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical activity level
Number of subjects: 988
Study 25403550 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate physical activity level
Number of subjects: 988
Study 25403550 — intervention group
Group type: EXPERIMENTAL
Intervention: Low physical activity level
Number of subjects: 988
Study 25403830 — intervention group
Group type: EXPERIMENTAL
Intervention: vosaroxin 72 mg/m² d 1, 4
Number of subjects: 116
Study 25403830 — intervention group
Group type: EXPERIMENTAL
Intervention: vosaroxin 72 mg/m² d 1, 8, 15
Number of subjects: 116
Study 25403830 — intervention group
Group type: EXPERIMENTAL
Intervention: vosaroxin 72 mg/m² d 1, 8
Number of subjects: 116
Study 25403830 — intervention group
Group type: EXPERIMENTAL
Intervention: vosaroxin 90 mg/m² d 1, 4
Number of subjects: 116
Study 25403830 — intervention group
Group type: EXPERIMENTAL
Intervention: vosaroxin (all schedules)
Number of subjects: 116
Study 25404094 — intervention group
Group type: EXPERIMENTAL
Intervention: Belinostat (1000 mg/m² intravenously ×5 days of a 21-day cycle)
Number of subjects: 53
Study 25404145 — intervention group
Group type: EXPERIMENTAL
Intervention: Transference Work Scale (TWS)
Number of subjects: 0
Study 25404412 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculin Skin Test (TST)
Number of subjects: 308
Study 25404412 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON(®)-TB GOLD (QFT-G)
Number of subjects: 308
Study 25404952 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of LY2811376
Number of subjects: 18
Study 25404952 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg of LY2811376
Number of subjects: 18
Study 25404952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 25405275 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG surgery
Number of subjects: 84
Study 25405351 — intervention group
Group type: EXPERIMENTAL
Intervention: Baminercept (lymphotoxin-beta receptor-immunoglobulin fusion protein)
Number of subjects: 0
Study 25405497 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin concentrations
Number of subjects: 634
Study 25405497 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin concentrations
Number of subjects: 634
Study 25405497 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin concentrations
Number of subjects: 634
Study 25405500 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyskeratosis congenita (DC)
Number of subjects: 5
Study 25405500 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond-Blackfan anemia (DBA)
Number of subjects: 5
Study 25405500 — intervention group
Group type: COMPARATOR
Intervention: Fanconi anemia (FA)
Number of subjects: 5
Study 25405614 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day antibiotic therapy during acute exacerbations
Number of subjects: 142
Study 25405614 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchiectasis symptoms for 10 years or greater
Number of subjects: 142
Study 25405614 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum culture positive for Pseudomonas aeruginosa
Number of subjects: 142
Study 25405614 — intervention group
Group type: EXPERIMENTAL
Intervention: HRCT total score being 12 or greater
Number of subjects: 142
Study 25405614 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 or more bronchiectatic lobes
Number of subjects: 142
Study 25405619 — intervention group
Group type: EXPERIMENTAL
Intervention: High for age carotid-femoral pulse wave velocity (PWV)
Number of subjects: 205
Study 25405619 — intervention group
Group type: EXPERIMENTAL
Intervention: Known hypertension
Number of subjects: 205
Study 25405619 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 205
Study 25405619 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of carotid plaque
Number of subjects: 205
Study 25405619 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher systolic BP
Number of subjects: 205
Study 25405619 — intervention group
Group type: EXPERIMENTAL
Intervention: History of hypertension
Number of subjects: 205
Study 25405619 — intervention group
Group type: EXPERIMENTAL
Intervention: Low HDL cholesterol
Number of subjects: 205
Study 25405619 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum creatinine
Number of subjects: 205
Study 25405724 — intervention group
Group type: EXPERIMENTAL
Intervention: NF54 strain Plasmodium falciparum by the bite of five infected Anopheles stephensi mosquitoes
Number of subjects: 6
Study 25405724 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine by directly observed therapy
Number of subjects: 6
Study 25405724 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring for signs and symptoms of malaria and for parasitemia by peripheral blood smear
Number of subjects: 6
Study 25405724 — intervention group
Group type: EXPERIMENTAL
Intervention: qRT-PCR
Number of subjects: 6
Study 25405724 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody response to merozoite surface protein 1 (MSP-1)
Number of subjects: 6
Study 25405724 — intervention group
Group type: EXPERIMENTAL
Intervention: Humoral and cellular responses to pre-erythrocytic antigens CSP and LSA-1
Number of subjects: 6
Study 25406275 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent class analysis (LCA) of fundus autofluorescence (FAF) patterns
Number of subjects: 171
Study 25406275 — intervention group
Group type: COMPARATOR
Intervention: Original classification of FAF patterns
Number of subjects: 171
Study 25406369 — intervention group
Group type: EXPERIMENTAL
Intervention: BAsE-Seq method for obtaining long haplotypes from short sequence reads
Number of subjects: 0
Study 25406369 — intervention group
Group type: EXPERIMENTAL
Intervention: BAsE-Seq applied to a clinical sample
Number of subjects: 0
Study 25406639 — intervention group
Group type: EXPERIMENTAL
Intervention: Locking compression plate (LCP) for the superior anterior clavicle (Synthes®)
Number of subjects: 20
Study 25406723 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous transplantation of mesenchymal stem cells
Number of subjects: 14
Study 25406739 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelium-dependent, flow-mediated vasodilation (FMD) technique using high-resolution B-mode ultrasound
Number of subjects: 0
Study 25407698 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month lifestyle intervention program including diet and physical exercise
Number of subjects: 39
Study 25407698 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 39
Study 25408112 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 concentration at admission in ADHF patients
Number of subjects: 132
Study 25408112 — intervention group
Group type: COMPARATOR
Intervention: Angiopoietin-2 concentration at admission in healthy controls
Number of subjects: 132
Study 25408112 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 concentration in ADHF patients with peripheral oedema
Number of subjects: 132
Study 25408112 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 concentration in ADHF patients without peripheral oedema
Number of subjects: 132
Study 25408112 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 concentration in ADHF patients with NYHA class III or IV symptoms
Number of subjects: 132
Study 25408112 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 concentration in ADHF patients with NYHA class II symptoms
Number of subjects: 132
Study 25408112 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 concentration at discharge in survivors
Number of subjects: 132
Study 25408112 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 concentration at admission in non-survivors
Number of subjects: 132
Study 25408112 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 concentration at discharge in non-survivors
Number of subjects: 132
Study 25408112 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiopoietin-2 concentrations at discharge above 2,500 pg/ml
Number of subjects: 132
Study 25408147 — intervention group
Group type: EXPERIMENTAL
Intervention: SFRP4 concentrations
Number of subjects: 504
Study 25408662 — intervention group
Group type: EXPERIMENTAL
Intervention: lanreotide Autogel(®) 120 mg, administered as monthly deep-subcutaneous injections
Number of subjects: 1
Study 25408662 — intervention group
Group type: COMPARATOR
Intervention: octreotide long-acting release (LAR) 30 mg monthly
Number of subjects: 1
Study 25408662 — intervention group
Group type: EXPERIMENTAL
Intervention: chemotherapy treatment with cisplatinum-etoposide
Number of subjects: 1
Study 25409372 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV8 vector gene therapy (high dose: 2×10(12) vector genomes per kg)
Number of subjects: 10
Study 25409372 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV8 vector gene therapy (high dose)
Number of subjects: 10
Study 25409372 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV8 vector gene therapy
Number of subjects: 10
Study 25410548 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized operating room to intensive care unit handoff process
Number of subjects: 0
Study 25411038 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with elevated HRP2
Number of subjects: 451
Study 25411038 — intervention group
Group type: COMPARATOR
Intervention: Adjustment for HRP2 and APP
Number of subjects: 451